IMPORTANCE Germline pathogenic variants in BRCA1 and BRCA2 predispose to an increased lifetime risk of breast cancer. However, the relevance of germline variants in other genes from multigene hereditary cancer testing panels is not well defined.
R ecent improvements in DNA sequencing technology have led to the development of multigene panels for clinical genetic testing of several conditions. In particular, panels targeting genes implicated in cancer susceptibility have increased the likelihood of detecting cancerpredisposing variants and offer advantages in time and cost compared with single gene testing. [1] [2] [3] A broad range of cancer susceptibility panels are available from genetic testing laboratories. 1, [4] [5] [6] These include high-penetrance BRCA1 and BRCA2 breast and ovarian cancer genes; mismatch repair genes; high-penetrance CDH1, PTEN, STK11, and TP53 genes that are associated with hereditary diffuse gastric cancer as well as Cowden disease, Peutz-Jeghers syndrome, and Li-Fraumeni syndrome, respectively; and genes associated with moderate risks of breast cancer (2-fold to 5-fold), such as CHEK2 and ATM. 7, 8 Patients with pathogenic variants in any of these genes are eligible for increased surveillance for cancer or other preventive measures. Cancer gene testing panels identify variants in substantial proportions of patients. 1, 4, 6 However, the frequency of variants in each of the panel genes among individuals qualifying for clinical genetic testing remains to be defined, and the risks of breast and other cancers associated with variants in many panel genes are not established. In this study, we report on the risks of breast cancer associated with inactivating variants in these genes identified by clinical genetic testing of patients with breast cancer by 1 laboratory.
Methods

Study Population
Study participants included a nationwide sample of 65 057 women with breast cancer referred for hereditary cancer genetic testing by Ambry Genetics Inc between March 15, 2012 , and June 30, 2016. The mean (SD) age at diagnosis for the 65 057 women included in the analysis was 48.5 (11.1) years. Demographic, clinical history, and family history of cancer information (eTable 1 and eTable 2 in the Supplement) were collected from test requisition forms, clinic notes, and pedigrees provided by ordering clinicians at the time of testing. Information was collected on current age, personal history, and age at diagnosis of all cancers, ancestry, tumor pathology, family history of cancer with cancer type, and age at diagnosis among relatives. The study was approved by the solutions institutional review board, which also determined that this study was exempt from consent requirements.
Phenotype Data
A potential limitation of this study is the quality and quantity of the clinical history information collected for the paneltested patients. The variant frequencies and breast cancer risk estimates from this study were derived from probands and were not dependent on family history information. To assess data quality, a review of a random sample of 1200 breast and ovarian cancer patient intake forms was conducted. Of these, 520 (43.3%) forms had additional clinical history documentation available. The accuracy of personal cancer history was greater than 97% (eMethods in the Supplement).
Multigene Panel Testing
Mutation testing was performed by targeted custom capture and sequencing and targeted chromosomal microarray analysis (eMethods in the Supplement). 1 Results from germline genetic testing of 21 known and candidate breast cancer predisposition genes from custom capture sequencing panels (BreastNext, OvaNext, PancNext, CancerNext, CancerNextExpanded, ColoNext, BRCAplus, BRCAplus-Expanded, and GYNplus; all Ambry Genetics Inc) (eTable 3 in the Supplement) were included in this study. A 5-tier variant classification system (eTable 4 in the Supplement) 9 was applied to all alterations. All variants identified by Ambry Genetics Inc are submitted to the ClinVar public database (https://www.ncbi .nlm.nih.gov/clinvar/).
variants and any missense variants (defined as pathogenic in ClinVar by clinical laboratories) in breast cancer cases and ExAC controls were selected for analysis. Filtering steps were applied (eMethods in the Supplement) to normalize differences in the breast cancer cases and ExAC controls. Variants with minor allele frequency greater than 0.3% other than common founder mutations were excluded (eTable 5 and eMethods in the Supplement). All suspected mosaic somatic variants (allele ratio >70:30) and truncating variants in the last 55 base pairs of the penultimate exon or last exon that potentially avoid nonsense-mediated messenger RNA decay and do not influence known functional domains were excluded. Large genomic rearrangements of 1 or more exons were excluded because rearrangements were not validated among reference controls. (eFigure in the Supplement).
Statistical Analysis
Associations between pooled pathogenic variants in each gene (eTable 6 in the Supplement) and phenotypic characteristics of breast cancer cases were assessed using the Fisher exact test. Associations with age at diagnosis were estimated using the Kolmogorov-Smirnov test. The observed frequency of all pathogenic variants within each gene was compared between white patients with breast cancer and ExAC-NFE non-TCGA reference controls. Strength of associations with breast cancer was estimated by odds ratios (ORs) and corresponding 95% CIs based on the Fisher exact test (Table; eTable 7 in the Supplement). P < .05 was considered statistically significant. Genes were categorized as high risk (OR, >5.0), moderate risk (OR, 2.0-5.0), or no clinical relevance (OR, <2.0). A series of sensitivity analyses were performed for truncating variants only; cases with pathogenic variants in more than 1 gene; BreastNext-tested cases; all ethnicities combined; and ExAC-NFE nonTCGA PASS reference controls; exclusion of cases with prior testing of BRCA1 (GenBank, NM_007294.3) and BRCA2 (GenBank, NM_000059.3); exclusion of ductal carcinoma in situ; and exclusion of cases with a personal or family history of ovarian or colorectal cancer (eTables 8-17 in the Supplement). ) and RAD51D (GenBank, NM_002878.3) (OR, 3.07; 95%, CI 1.21-7.88; P = .01) were significantly associated with moderate risks (Table) , whereas MSH6 (GenBank, NM_000179.2) (OR, 1.93; 95% CI, 1.16-3.27; P = .01) was only marginally below the moderate-risk threshold (OR, ≥2) (Table) . Variants in both MSH2 and CDKN2A (GenBank, NM_000249.3) yielded moderate effects, but both associations were nonsignificant due to limited numbers of variants in cases and controls (Table) . BRIP1 mutations conferred only a slightly increased risk of breast cancer (OR, 1.63; 95% CI, 1.11-2.41; P = .01), consistent with results from a case-control study involving familial cases (relative risk [RR], 2.0; 95% CI, 1.3-3.0; P = .01). 16 Similarly, RAD51C, NF1 (GenBank, NM_000267.3), and the MRN complex genes NBN (GenBank, NM_002485.4), MRE11A (GenBank, NM_005591.3), and RAD50 (GenBank, NM _005732.3) were not associated with increased breast cancer risks (Table) . 17 Associations between pooled pathogenic variants in BRCA1, BRCA2, and the CDH1 (GenBank, NM _004360.4), PTEN (NM_000314.6), and TP53 syndromic genes were also assessed (eTable 7 in the Supplement). However, the attenuated risks associated with BRCA1 and BRCA2 pathogenic variants resulting from an enrichment of the cohort for patients who previously tested negative for these genes must be interpreted with care. Similarly, risk estimates for CDH1, PTEN, and TP53 were based on very small numbers of patients with pathogenic variants and may also be influenced by limited ascertainment of patients with the associated clinical syndromes. None of the 23 patients with CDH1 pathogenic variants reported a personal history of gastric cancer. A series of sensitivity analyses were also performed to assess the influence of various subsets of patients with breast cancer and ExAC control selection on the associations with breast cancer. Effect sizes of associations were consistently inflated for the 16 genes when using ExAC-NFE non-TCGA PASS reference controls instead of PASS/non-PASS controls (eTable 8 in the Supplement). For example, BARD1 variants showed effects ranging from ORs of 2.16 to 3.18, and PALB2 variants ranged from ORs of 7.46 to 8.66 (Table and eTable 8 in the  Supplement) . Associations for each gene were also estimated after exclusion of patients with breast cancer reporting prior testing for BRCA1, BRCA2, or multigene panels. Results were consistent with those from the primary analysis (eTable 9 in the Supplement). In addition, a sensitivity analysis of patients tested only by the BreastNext panel was conducted to assess whether combining results from multiple panels that did not always contain the full complement of genes influenced the combined allele frequencies and the estimated risks of breast cancer. Only minor changes in risk estimates were observed (eTable 13 in the Supplement). Sensitivity analyses were also conducted when restricting analysis to pathogenic protein-truncating variants (eTable 10 in the Supplement), excluding ductal carcinoma in situ (eTable 11 in the Supplement), and including patients with pathogenic variants in multiple genes (eTable 12 in the Supplement). Results for each gene were highly consistent across all of these analyses. In contrast, no associations with breast cancer were observed for the mismatch repair genes when excluding all patients with personal and family history of ovarian and/or colorectal cancer (eTables 14-16 in the Supplement). Similarly, associations between pathogenic variants in RAD51D were attenuated when including patients of all ethnicities and ExAC non-TCGA PASS reference controls due to recurrent variants in the South East Asian reference population (eTable 17 in the Supplement).
Results
Characteristics of Study Population
Discussion
We present results from multigene panel-based clinical testing for pathogenic variants in inherited cancer genes among 65 057 patients with breast cancer. Pathogenic variants in 21 panel genes were identified in 10.2% of white women with breast cancer and in 6.2% of women with breast cancer after exclusion of BRCA1 and BRCA2. These findings were somewhat consistent with the 3.8%, 6 3.9%, 17 and 4.6% 18 variant frequencies from other studies of breast cancer cases enriched for a family history of breast and/or other cancers. This study provides insight into genes with pathogenic variants that predispose to moderate and high risks of breast cancer. In total, 5 of 16 non-BRCA1/2, nonsyndromic panel genes were significantly associated with moderate or high (OR, >2) breast cancer risk in the white population (PALB2, ATM, CHEK2, BARD1, and RAD51D). PALB2 was confirmed as a high-risk breast cancer gene (OR, 7.46; 95% CI, 5.12-11.19) in this testing population, consistent with a cumulative lifetime risk of up to 58% for breast cancer from family segregation studies. 13 We also confirmed that CHEK2 and ATM are associated with increased breast cancer risk. 5 Several stratified analyses of the patients with breast cancer and the ExAC reference controls in this study also provided consistent results. These findings provide further support for the National Comprehensive Cancer Network recommendations, version 1.2017 (http: //www.nccn.org/professionals/physician_gls/f_guidelines .asp#detection) for management of treatment for patients with pathogenic ATM, CHEK2, and PALB2 variants.
We establish that pathogenic variants in BARD1 and RAD51D are associated with moderately increased risks of breast cancer. Because pathogenic variants in these genes are rare (<1 in 500 in patients with breast cancer), previous studies had insufficient numbers of breast cancer cases and controls to adequately assess the influence of pathogenic variants in these genes on breast cancer risk. 5 This was possible only by using more than 25 000 patients with breast cancer and reference controls in this study. Additional studies of patients with BARD1 and RAD51D variants are now needed to better understand the related breast cancer phenotypes. Furthermore, MSH6 pathogenic variants were associated with near-moderate risks (OR, 1.93; 95% CI, 1.16-3.27) of breast cancer, contrary to a previous study suggesting little influence of mismatch repair gene mutations on breast cancer risk. 19 However, excluding patients with breast cancer who had a personal or family history of colorectal cancer removed all evidence of an influence on breast cancer. Family-based segregation studies will be needed to determine whether variants in this gene have no influence on breast cancer risk or predispose to complex phenotypes involving breast and colorectal cancer. Additional studies of the influence of CDKN2A and MSH2 on breast cancer are also needed following the observation that pathogenic variants in these genes may be associated with moderate breast cancer risk.
Of equal importance, however, are the findings that pathogenic variants in NF1, BRIP1, RAD51C, the MLH1 (GenBank, NM _000249.3) and PMS2 (GenBank, NM_000535.6) mismatch repair genes, and the MRE11A, RAD50, and NBN MRN complex genes did not confer any appreciable risks of breast cancer. Although the BRIP1 ovarian cancer gene was associated with modestly increased risk of breast cancer overall (OR, 1.63; 95% CI, 1.11-2.41), exclusion of cases with a personal or family history of ovarian cancer to account in part for competing risks of cancer substantially reduced the risks of breast cancer (OR, 1.27; 95% CI, 0.81-1.99) to effect sizes observed for the BRIP1 p.Arg798Ter variant (OR, 1.09; 95% CI, 0.58-2.03) in other large case-control studies. 20 In contrast, the results for NBN differed from those in a large study of the Slavic founder variant (c.657del5) that associated the variant with a moderate risk of breast cancer (RR, 2.4; 95% CI, 1.9-3.7). 21 Likewise, pathogenic variants in NF1 among patients with neurofibromatosis have been associated with moderate risks of breast cancer (RR, 2.6; 95% CI, 2.1-3.2), 22,23 whereas we failed to observe any influence on breast cancer risk. Thus, additional studies of the influence of NF1 pathogenic variants on breast cancer risk in individuals with and without neurofibromatosis are needed. In contrast, results demonstrating no increased risk for breast cancer for pathogenic variants in RAD51C, MLH1, PMS2, RAD50, MRE11A, and NBN were consistent across all stratified analyses, suggesting that these genes may not be relevant in clinical testing for breast cancer risk. However, it remains to be determined whether specific missense variants in these genes influence risk.
We acknowledge the limitations of the public reference data set; however, extensive data cleaning and filtering were used in an effort to normalize the breast cancer cases and control data.
Limitations
This study was focused on patients qualifying for clinical genetic testing and was not a population-based study. In addition, associations between pathogenic variants in panel genes and breast cancer were evaluated using sequencing results from breast cancer cases and the database of ExAC reference samples. The use of results from unmatched cases and controls that were sequenced on different platforms could have caused inflation of ORs for breast cancer. This limitation could be addressed in the future using combined case-control studies matched on age and race. However, when considering sequence quality, variant allele frequency, race, and ethnicity, and excluding known cancer samples, the ExAC-NFE non-TCGA data set offered a reasonable approximation of white population-based allele frequencies. 24 ExAC controls have been used to identify genes that predispose to ovarian and prostate cancer, 11, 12 to exclude other genes from involvement in these cancers, and to approximate risks associated with variants when comparing ExAC data with variants detected on other platforms. 12 Similarly, ExAC data have been used to evaluate genes associated with increased cardiovascular risk. 25 Thus, although variants in ExAC and ovarian or prostate cancer cases were derived from different sequencing platforms and were identified using different algorithms, the studies successfully identified genes associated with increased risks.
Conclusions
We present breast cancer risk estimates in a clinical, multigene panel testing cohort as useful indicators of the clinical relevance of pathogenic variants in breast cancer susceptibility genes. The breast cancer cases qualifying for clinical genetic testing were enriched for a clinical history of earlyonset, bilateral, and triple-negative breast disease and a family history of breast cancer. Therefore, the risk estimates derived in this study are likely to be inflated over estimates from population-based studies, as previously reported for PALB2 pathogenic variants from high-risk families. 13 Although the risks presented herein may not be generalizable to all mutation carriers, they are highly relevant to those with clinical histories suggestive of hereditary breast cancer predisposition. Future studies involving patients with breast cancer unselected for age at diagnosis, tumor pathology, and family cancer history and incorporating a broader range of alterations in addition to segregation studies in families are needed to further inform breast cancer risks for mutation carriers.
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PMS2
c.736_741del6ins11 Pathogenic Mutation
The c.736_741del6ins11 pathogenic mutation (also known as c.736_741delCCCCCTinsTGTGTGTGAAG), located in coding exon 7 of the PMS2 gene, results from the deletion of 6 nucleotides and an insertion of 11 nucleotides, causing a translational frameshift with a predicted alternate stop codon. Multiple studies have identified this mutation in association with clinical findings consistent with a diagnosis of HNPCC/Lynch syndrome syndrome [11] [12] [13] [14] [15] . Subsequent family studies have identified this mutation as a founder mutation that arose ~1625 years ago and is enriched in individuals with British and Swedish ancestry and have also suggested that this mutation may have reduced penetrance 12 . In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation 16 . 
DNA Sequencing
Patients underwent comprehensive analysis of 5 to 49 cancer susceptibility genes, depending on the panel ordered (eTable 2). Genomic deoxyribonucleic acid (gDNA) was isolated from the patient's blood or saliva specimen using a standardized methodology (Qiagen, Valencia, CA) and then quantified using a spectrophotometer (Nanodrop; Thermoscientific, Pittsburgh, PA, or Infinite F200; Tecan, San Jose, CA). Sequence enrichment was performed by incorporating the gDNA onto microfluidics chip or into microdroplets along with primer pairs or by a bait-capture methodology using long biotinylated oligonucleotide probes (RainDance Technologies, Billerica, MA or Integrated DNA Technologies, San Diego, CA), followed by PCR and then NGS analysis (Illumina, San Diego, CA) of all coding exons plus at least five bases into the 5' and 3' ends of all the introns and untranslated regions (5'UTR and 3'UTR). Sanger sequencing was performed for any regions with insufficient depth of coverage for reliable heterozygous variant detection and for verification of all variant calls other than known nonpathogenic alterations. A targeted chromosomal microarray designed with increased probe density in regions of interest was used for the detection of gross deletions and duplications for all genes in which gross deletions and duplications are reported except PMS2 (Agilent, Santa Clara, CA). Gross deletion/duplication analysis of PMS2 was performed using MLPA kit# P008-B1 (MRC-Holland, Amsterdam, Netherlands). If a deletion was detected in select exons (13, 14, or 15 and in some cases 12) of PMS2, double stranded sequencing of the appropriate exon(s) of the pseudogene PMS2CL was performed to determine if the deletion was located in the PMS2 gene or pseudogene. Initial data processing and base calling, including extraction of cluster intensities, was done using RTA 1.12.4 (HiSeq Control Software 1.4.5; Illumina). Sequence quality filtering was executed with the CASAVA software (version 1.8.2; Illumina, Hayward, CA). Sequence fragments were aligned to the reference human genome (GRCh37), and variant calls were generated using CASAVA. A minimum quality threshold of Q20 was applied, translating to an accuracy of >99.9% for called bases. Variants were annotated with the Ambry Variant Analyzer, a proprietary alignment and variant annotation software (Ambry Genetics).
Quality assessment of phenotype data To assess data quality, a review of a random sample of 1200 (10%) breast and ovarian cancer patient intake forms was conducted. Of these, 43.3% (520 of 1200) with additional clinical history documentation available (clinic notes, pedigrees, detailed letters of medical necessity). Consistent information was observed for 100% (429/429) of breast cancers, 99.5% (409/411) for age at breast cancer diagnosis, 99.7% (331/332) for breast tumor pathology, 97.9% (275/281) for breast tumor hormone receptors status, 100% (90/90) for ovarian cancer, and 100% (88/88) for age at ovarian cancer diagnosis, suggesting that the intake data for the cohort is of reasonably high quality.
Family history Family history was limited to first and second-degree relatives. Families with breast or ovarian cancer in two or more individuals, on the same parental side, were considered positive for family history for each cancer. MUTYH mutations were excluded from the analysis because MUTYH-associated polyposis is considered an autosomal recessive condition. 
Data cleaning and filtering rules
